𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and leukemia group B (CALGB) study 8353

✍ Scribed by Rybak, Mary Ellen ;McCarroll, Kathleen ;Kaplan, Richard J. ;Propert, Kathleen J. ;Budman, Daniel R. ;Gottlieb, Arlan J.

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
394 KB
Volume
18
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A phase II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed Hodgkin's disease (HD) to assess the activity of the combination of etoposide and cis‐platin. Twenty‐seven patients were entered; 22 were evaluated for this report. Treatment consisted of etoposide (VP‐16), 80 mg/m^2^ IV over 1 hour and cis‐platin, 20 mg/m^2^IV over 1/2‐1 hour; both agents were given daily for 5 days and repeated every 21 days. All patients had received at least 2 prior chemotherapy regimens, had measurable disease, and most (86%) had a performance status of 0‐1. In the 22 evaluable patients, there were 4 complete responses (18%) and 4 partial responses, for an overall response rate of 36% (95% Cl: 17.2%, 59.3%). Response duration was from 2.1 to 31 months. Significant toxicity was observed with this regimen. Ten patients (45%) had leukopenia <1,000/μl, and 11 patients (50%) had thrombocytopenia <25,000/μl. Serum creatinine levels reached >2.0 in 14% of patients. Seven patients (32%) had severe nausea and vomiting. VP‐16, cis‐platin appears to be an active combination in HD; however, their combined activity is only marginally better than reported single‐agent activity for VP‐16 in the doses and schedule used. Further studies of related combinations in HD are currently under evaluation by the CALGB.

📜 SIMILAR VOLUMES

Phase II trial of etoposide and cisplati
Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351
✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552
✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of ifosfamide/mesna and m
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753
✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day × 3) with mesna (400 mg/m^2^ intravenously q 4 h daily × 3) was combined with mitoxantrone (14 mg/m^2^ intravenously × 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients

Sequential chemotherapy (etoposide, vinb
Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized hodgkin disease and unfavorable prognostic features : A phase II cancer and leukemia group B study (9051)
✍ Todd H. Wasserman; Gina R. Petroni; Frederick E. Millard; Chung-Taik Chung; Maur 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

The aim of this study was to evaluate a regimen of sequential chemotherapy and radiotherapy for patients with Hodgkin disease. ## METHODS. The Cancer and Leukemia Group B conducted a Phase II study of three cycles of etoposide, vinblastine, and doxorubicin (EVA) chemotherapy followed by subtotal

A Phase II study of estramustine, doceta
A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813
✍ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor (G‐CSF) support in patients with hormone‐refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,